Menu
- Things To Do Las Vegas
- car rental Malaga
- myrtle beach golf packages
- Australia Car Rental
- New Zealand Car Hire
Travel immunizations
Vincent Lo Re, IIIAs international travel to exotic locations becomes increasingly common, it is necessary for more physicians to maintain familiarity with current recommendations for travel health safety. Immunizations and preventive medicines are key parts of travel preparation, and careful attention to them can reduce the risks of infections acquired while abroad. Travel vaccines generally fall into one of three categories: (1) routine immunizations typically administered during child-hood that should be updated or boosted, (2) legally required immunizations necessary for entry into certain countries, and (3) recommended immunizations that may be useful, depending on the risks of expo-sure at the travel destination. (1-3) Vaccines are not available for all travel-related infections (e.g., malaria). In these cases, preventive medication may be necessary to keep the traveler healthy.
Advising travelers on vaccine- and medication-preventable diseases is increasingly becoming the responsibility of primary care physicians. The approach to travel health recommendations should be based on an assessment of the risks for travel-related illnesses, the time available before trip departure, and the current epidemiology of preventable diseases. Physicians should take into account the adverse events and contraindications associated with each vaccine and medication. This article reviews the overall approach to travel immunizations and provides an overview of the immunizations that are recommended or required for international travel (Table 1). Information about preventive medication has appeared previously in American Family Physician. (4)
Risk Assessment
Immunizations should be recommended according to the patient's risk of travel-related diseases and not solely according to geographic destination. A number of resources provide updated information about risks to travelers (Table 2). (5) To properly assess a traveler's risk of illness, the physician first should consider the details of the planned journey (5-7) the exact itinerary, including all geographic destinations and possible stopovers; duration of stay in each location; type of lodging (urban or rural, hotel or tent); planned activities (animal contact, river- or lake-water exposure, eating habits); seasonal risks (time of year); and level of anticipated contact with local residents.
Physicians then should review the status of the traveler's general health, focusing on underlying diseases that may have implications during the trip. (6) Previous immunizations, allergies to medications and vaccine components (especially eggs), and current medications also should be reviewed. (5-7) The physician should make a special effort to identify travelers who are at particularly high risk for travel-related illnesses (Table 3). (3,6) An overall approach to vaccination of travelers based on risk assessment is presented in Figure 1 and Table 4.
[FIGURE 1 OMITTED]
Travelers, particularly those going to developing countries, should be encouraged to seek medical advice early in their planning (at least four weeks in advance). Consultation with a travel clinic may be helpful if the destination is high risk. The amount of time remaining before departure determines whether the standard schedule for a primary immunization series can be used or whether an accelerated schedule, if one exists, should be offered. (2) When departure is imminent and an accelerated vaccine schedule is used, vaccine efficacy may not be maximal by the time of departure, and this fact must be discussed with the patient. (2)
Physicians who provide consultations to travelers should base their recommendations on the current epidemiology of vaccine-preventable diseases at each destination. The Centers for Disease Control and Prevention (CDC) publication, "Health Information for International Travel," is one of the standard references for travel immunization recommendations and is updated regularly. (8) Additional information may be obtained online from the CDC (http://www.cdc.gov/travel) and the World Health Organization (WHO) (http://www.who.int/ith).
Routine Immunizations
Travel provides an opportunity for the physician to review and update a patient's routine immunizations. (1,6) Travelers to areas where postexposure tetanus immunization might be unavailable should consider receiving a booster dose of tetanus and diphtheria (Td) toxoids before departure if five or more years have elapsed since their last vaccination. (9)
Measles is endemic in many developing nations, and a booster of measles-mumps-rubella (MMR) vaccine is warranted for any person born after 1956 who does not have documentation of two doses of the vaccine or immunity by serum antibody testing. (10) Children six to 11 months of age should receive one dose of MMR vaccine if traveling to highly endemic areas, but they still must receive two doses of the vaccine after 12 months of age to be considered fully immunized. (10)
Polio is a good example of the need for physicians to keep current with changing epidemiology. Intensive immunization campaigns have resulted in a marked decrease in polio throughout the world. Polio remains endemic in seven countries: India, Nigeria, Pakistan, Egypt, Afghanistan, Niger, and Somalia. (11) Travelers to these countries are advised to receive a single booster of inactivated polio vaccine (IPOL) if the primary doses have already been administered.
Varicella (chickenpox) immunity should be reviewed and, if needed, children one through 12 years of age should receive a single dose of vaccine (Varivax), while those 13 years and older should receive two doses of vaccine administered four to eight weeks apart. (1,2,8,12,13) In particular, this vaccine should be considered for women of child-bearing age who do not have documented varicella disease before vaccination or anti-body titers.
The pneumococcal vaccine (Pneumovax) should be considered for travelers who are older than 65 years as well as younger adults with chronic cardiopulmonary disease, asplenia, cirrhosis, or diabetes mellitus. (8,14)
Finally, the influenza vaccine is recommended for all international travelers during influenza season. While influenza typically occurs from November until March in the northern hemisphere, the incidence of the disease peaks from April until September in the southern hemisphere. Patients should receive the most current vaccine available.
Required Immunizations
YELLOW FEVER
Yellow fever is a rare but potentially fatal viral infection that is endemic in equatorial Africa (Figure 2) and South America (Figure 3), where the virus is transmitted by day-biting mosquito vectors. (15) The clinical presentation of the disease ranges from a mild febrile illness to a life-threatening disease characterized by hepatitis, renal failure, hemorrhagic fever, and shock.
Yellow fever vaccination is recommended for patients older than nine months who are traveling to areas where yellow fever is reported. (15) It also is recommended for travelers to rural areas of countries that do not officially report yellow fever but are within the endemic zone. (15) Many yellow-fever endemic countries require proof of vaccination for entry. Other countries may require proof of vaccination if a person is traveling from an endemic area to prevent introduction of the disease. Yellow fever vaccination may be required even if the person merely passes through an endemic region while traveling to the final destination. Physicians can obtain country-specific requirements for yellow fever vaccination from the CDC. (8)
The yellow fever vaccine (YF-Vax) is a live-attenuated virus preparation delivered in a single subcutaneous inoculation of 0.5 mL. It induces neutralizing antibodies in 99 percent of recipients within 30 days of receipt. (16) Immunity is likely to be lifelong, but revaccination is required at 10-year intervals. (15) For purposes of international travel, the vaccine must be administered at an approved yellow fever vaccination center. Proof of immunization should be documented on an Official International Certificate of Vaccination Against Yellow Fever, which becomes valid 10 days after vaccination to meet entry and exit requirements for all countries. Yellow fever immunization is usually avail-able at local health departments, which are approved vaccination centers.
Reactions to the yellow fever vaccine are generally mild, but analysis of vaccine recipients in the United States from 1990 to 1998 found that persons 65 years or older were at an increased risk for neurologic and systemic reactions. (17) [Evidence level B, case series] Thus, its use should be considered carefully in this population.
Yellow fever vaccination is not recommended in pregnancy, and pregnant women who are not immune to yellow fever should delay their travel to any high-transmission area until after delivery. If the travel itinerary of a pregnant woman does not present a substantial risk, and immunization is required only for entry, the physician should provide the woman with a waiver letter. (8,15)
[Evidence level C, consensus/expert guidelines] Pregnant women who must travel to areas with active transmission should be vaccinated because the small risk to the mother and fetus from the vaccine is believed to be outweighed by the risk of yellow fever. (15) [Evidence level C, consensus/expert guidelines]
Recommended Immunizations
HEPATITIS A
The inactivated hepatitis A virus vaccines (Havrix, Vaqta) are recommended for all international travelers except those going to destinations in North America (except Mexico), western Europe, Japan, Australia, and New Zealand. (8,18,19) Travelers preferably should receive a single intramuscular dose of 1.0 mL four weeks before departure. Vaccination two weeks before travel still may be useful because up to 94 percent of patients develop protective antibodies within two weeks of the first dose. (19) [Evidence level A, randomized controlled trial (RCT)] A 1.0-mL booster given six to 12 months later can provide protective antibody levels for at least 10 years. (19) Both vaccines provide protective antibody levels in 94 to 100 percent of patients within four weeks of vaccination. (20,21) [References 20 and 21--Evidence level A, RCTs] The safety of the vaccine in pregnant women has not been determined.
Travelers who need optimal hepatitis A protection earlier than two weeks after the first dose of hepatitis A vaccine should receive immune globulin with the first vaccine dose but at a different injection site. (8,19,22) Those who receive vaccination less than two weeks before departure and who do not receive immune globulin are still at risk of infection, so administration of immune globulin should be considered. 98,19) [Evidence level C, consensus/expert opinion] Simultaneous receipt of hepatitis A vaccine and immune globulin results in lower antibody titers than occur when only hepatitis A vaccine is given, but protective antibody levels exceed those achieved when immune globulin is given alone. (2,23) Immune globulin also should be offered to travelers who are allergic to the vaccine, younger than two years, or pregnant. (19) It is given by intramuscular injection and can provide protection in 85 to 90 percent of patients for three to five months, depending on the dose used (0.02 mL per kg or 0.06 mL per kg). (19)
HEPATITIS B
While childhood vaccination against hepatitis B now is routine in the United States, many adult travelers have never been immunized. (24) Hepatitis B vaccination should be considered for patients who have a potential for close contact with a local population that has a high rate of hepatitis B transmission, patients planning an extended stay (six months or longer) in an area where hepatitis B is endemic (e.g., South America, Africa, southeast Asia, South Pacific), those with a potential need for medical treatment while abroad, and those born overseas who are traveling back to their country of origin.
The standard schedule for administering the hepatitis B vaccine (Recombivax-HB, Engerix-B) in adults 20 years and older calls for three doses of vaccine (each 1.0 mL) at zero, one, and six months. An accelerated schedule with Engerix-B consists of vaccination at zero, one, and two months, with a booster given 12 months after the first dose. (8,25) The vaccine is not contraindicated in pregnancy. (8)
COMBINED HEPATITIS A AND B
A combination hepatitis A and B vaccine (Twinrix) containing the same antigenic components as Engerix-B and pediatric Havrix is available for use in adults older than 18 years. It is as efficacious as each of the monovalent vaccines. (25,26) Primary immunization occurs at zero, one, and six months. An accelerated schedule of zero, one, and three weeks, with a fourth dose 12 months after the first dose, is as efficacious as the standard schedule. (26) Its safety in pregnancy has not been determined.
JAPANESE ENCEPHALITIS
Japanese encephalitis virus, an arboviral infection transmitted by day-biting mosquitoes, is prevalent in the Indian subcontinent, China, Korea, Japan, and other southeast Asian countries. (27) The majority of human cases are asymptomatic, but the virus can cause severe encephalitis with residual neuropsychiatric sequelae.
Japanese encephalitis vaccine (Je-Vax) should be offered to patients who plan to remain for 30 days or longer in endemic areas during the transmission season, particularly if travel destinations might include rural areas. Vaccination also should be considered for short-term travelers who engage in extensive outdoor activities or visit areas of epidemic transmission.
Primary immunization in patients three years or older consists of three doses of 1.0 mL, each given by subcutaneous injection on days zero, seven, and 30. An accelerated schedule, in which doses are given on days zero, seven, and 14, can be used when departure is imminent. (27) The vaccine's efficacy is 91 percent after two doses. (28) [Evidence level A, RCT] A booster dose may be given three years after the primary series if continued exposure in high-risk areas is expected. Because generalized urticaria and angioedema of the face, lips, or oropharynx occasionally have occurred up to two weeks after immunization, the last dose of vaccine should be administered at least 10 days before trip departure. (27,29)
The safety of the vaccine in pregnancy has not been determined. Pregnant women who must travel to an area where the risk of Japanese encephalitis is high should be vaccinated when it is thought that the risks of immunization are outweighed by the risk of infection to the mother and fetus. (27) [Evidence level C, consensus/expert guidelines]
TYPHOID FEVER
Typhoid fever immunization is recommended for travelers going to highly endemic areas in Central and South America, the Indian subcontinent, and Africa. (30) It also is recommended for travelers who may be exposed to potentially contaminated food and drink, such as those journeying beyond the usual tourist routes. (30) Typhoid vaccines (Vivotif Berna, a live-attenuated oral Ty21a vaccine, and Typhim VI) are approximately 50 to 80 percent effective and cannot substitute for careful selection of food and drink.
Primary vaccination with oral Ty21a consists of one enteric-coated capsule taken on alternate days for four doses. (30) Vaccine-elicited immunity occurs 14 days after receipt of the last vaccine dose, with an overall efficacy of approximately 50 to 80 percent. (30) [Evidence level A, RCT] A booster dose, consisting of the entire four-capsule regimen, is recommended every five years for those at continued risk. (30) The most common adverse effect reported is mild gastrointestinal upset. The vaccine is contraindicated in pregnant women, children under the age of six years, and immunocompromised patients. Care must be taken if this vaccine is given in association with antibiotics because they may kill the live-attenuated organisms.
Primary vaccination with Typhim VI in patients two years or older consists of a single 0.5-mL dose given intramuscularly. Protective immunity is elicited 14 days after vaccine receipt. (30) The efficacy of this vaccine has been reported to be 50 to 80 percent. (8,30) [Evidence level A, RCT] A booster dose given every two years is recommended for continued exposure. No data have been reported regarding its use in pregnant women or immunocompromised patients, although it theoretically is a safer alternative in these groups.
MENINGOCOCCAL
Meningococcal vaccine (Menomune) is recommended for travelers to sub-Saharan Africa, where epidemics of serogroups A or C meningococcal disease occur frequently from December through June in the "meningitis belt" from Senegal to Ethiopia (31) (Figure 4). The vaccine is required for pilgrims to Saudi Arabia during the Hajj and at other religious holidays. (8)
The vaccine is effective only against sero-groups A, C, Y, and W-135.25,31 Primary immunization in patients two years and older consists of a single 0.5-mL dose given by subcutaneous injection, and this dose confers immunity for at least three years. (31) Protective levels of antibody are achieved in seven to 10 days. (8) Vaccination is not contra-indicated in pregnancy. (31) Revaccination may be considered within three to five years for continued exposure. (31)
RABIES
Canine rabies remains endemic in the Indian subcontinent, China, southeast Asia, the Philippines, parts of Indonesia, Latin America, Africa, and countries of the former Soviet Union. (1,2,32) Postexposure prophylaxis, although effective, may not be readily available. (33) Preexposure rabies vaccination should be considered for travelers who plan a prolonged stay (more than 30 days) in an endemic region, who travel in remote areas, work near animals, engage in activities that could attract animals (e.g., hiking, cycling), or for persons who cannot report an expo-sure if bitten (e.g., young children).
In the United States, intramuscular formulations of the purified chick embryo cell vaccine (RabAvert) and human diploid cell vaccine (Imovax) are available. Preexposure rabies immunization consists of three 1.0-mL doses of one of the rabies vaccine formulations given on days zero, seven, and 21 or 28.34 After a high-risk bite, travelers who received preexposure vaccination still require local wound care and two additional rabies vaccine doses (on the day of the bite and on day 3), but administration of rabies immune globulin is not necessary. (33)
TABLE 1
Common Vaccines for International Travelers
Vaccine Standard regimen Booster
Hepatitis A
Havrix 1.0 mL IM 1.0 mL IM 6 to 12
months after first
dose
Vaqta 1.0 mL IM 1.0 mL IM 6 to 12
months after first
dose
Hepatitis B
Recombivax-HB 1.0 mL IM at 0, 1 and A booster is not
6 months routine
Engerix-B 1.0 mL IM at 0, 1, 1.0 mL IM 12 months
and 6 months after first dose
(Accelerated
schedule: 1.0 ml
IM at 0, 1, and 12
months)
Combined hepatitis A
and hepatitis B
Twinrix 1.0 mL IM at 0, and 6 Not routine
months
Immune globulin
(human)
Baygam 0.02 to 0.06 mL per 0.02 to 0.06 mL per kg
kg every 3 to 5 months
Japanese encephalitis
Je-Vax 1.0 mL SQ on days, 1.0 mL SQ every 2 to
0, 7, 30 3 years
Meningococcal
Menomune 0.5 mL SQ 0.5 mL SQ every 3 to
5 years
Rabies
RabAvert 1.0 mL IM on days 0, Every 2 to 5 years
7, 21, or 28 (check serum for
antibody presence)
Imovax 1.0 mL IM on days 0, Every 2 to 5 years
7, 21, or 28 (check serum for
antibody presence)
Typhoid fever
Vivotif Berna Four-capsules: 1 Four-capsule regimen
(oral Ty21a) capsule given every every 5 years
other day
Typhim VI 0.5 mL IM 0.5 mL IM every 2
years
Yellow fever
YF-Vax 0.5 mL SQ 0.5 mL SQ every 10
years
Vaccine Age Adverse effects
Hepatitis A
Havrix [greater than or equal Injection site
to] 19 years soreness, headaches
([dagger])
Vaqta [greater than or equal Injection site
to] 19 years soreness, headaches
([dagger])
Hepatitis B
Recombivax-HB [greater than or equal Injection site
to] 20 years soreness, headaches
([dagger])
Engerix-B [greater than or equal Injection site
to] 20 years soreness, headaches
([dagger])
Combined hepatitis A
and hepatitis B
Twinrix [greater than or equal Injection site
to] 18 years soreness,
headaches, nausea
Immune globulin
(human)
Baygam [greater than or equal Injection site
to] 2 years soreness, urticaria
Japanese encephalitis
Je-Vax [greater than or equal Fever, headache,
to] 3 years nausea vomiting
(urticaria and
angioedema are
rare)
Meningococcal
Menomune [greater than or equal Injection site
to] 2 years soreness
Rabies
RabAvert All ages Myalgias,
lymphadenopathy
Imovax All ages Myalgias,
lymphadenopathy
Typhoid fever
Vivotif Berna [greater than or equal Nausea, vomiting,
(oral Ty21a) to] 6 years cramping, fever
Typhim VI [greater than or equal Nausea, vomiting,
to] 2 years cramping
Yellow fever
YF-Vax [greater than or equal Headaches, myalgias,
to] 9 months fever, encephalitis
(rarely in the
elderly
Vaccine Cost per * Notes
Hepatitis A
Havrix $64 Safety in pregnancy not
determined
Vaqta $78
Hepatitis B
Recombivax-HB $74 Safety in pregnancy not
determined
Engerix-B $60 Contraindicated in yeast
hypersensitivity
Combined hepatitis A
and hepatitis B
Twinrix $94 Safety in pregnancy not
determined
Immune globulin Contraindicated in yeast
(human) hypersensitivity
Baygam $31 for 2 mL Safety in pregnancy not
determined
Never shown to transmit
hepatitis B, hepatitis C,
or human immunodeficiency
virus
Avoid concurrent
administration with MMR
and varicella vaccines
Japanese encephalitis
Je-Vax $312 for 3 doses Safety in pregnancy not
determined
Administered last dose 10
days before trip
departure
Meningococcal
Menomune $80 Safe in pregnancy
Rabies
RabAvert $155 Give only if risk of
exposure to rabies is
substantial; pregnancy is
not a contraindication to
preexposure therapy
Imovax $160.59 After animal bite, rabies
vaccine on day of bite
and on day 3 required if
preexposure rabies
vaccine administered
(rabies immune globulin
not necessary)
Mefloquine or chloroquine
may interfere with immune
response to intradermal
Imovax vaccine if
administered concurrently
Typhoid fever
Vivotif Berna $43 for Oral Ty21a vaccine capsules
(oral Ty21a) 4 capsules must be kept
refrigerated; each
capsule should be taken
whole (do not chew)with
cool liquid one hour
before a meal
Oral Ty21a vaccine contra-
indicated in pregnancy
and immunocompromised
patients
Typhim VI $49 Start mefloquine (Lariam)or
chloroquine (Aralen) at
least 3 days after
completion of oral
Ty21a vaccine
Safety of Typhim VI vaccine
in pregnancy not
determined
Yellow fever
YF-Vax $162 Consider carefully in
elderly patients
Contraindicated in
pregnancy, patients with
egg allergy,and immuno-
compromised patients
Avoid concurrent
administration with other
live virus vaccines (MMR,
oral polio, varicella,
oral Ty21a)
IM = intramuscularly; SQ = subcutaneously; MMR = measles-mumps-rubella
vaccine.
*--Average wholesale cost, based on Red Book, Montvale, N.J.: Medical
Economics Data, 2003.
([dagger])--Pediatric concentration of vaccine available and/or requires
different dosage regimen.
TABLE 3
Travelers at High Risk for Travel-Related
Illnesses
Persons who backpack or trek while traveling
Persons older than 65 years
Persons living in the United States but
born in another country and who travel
back to country of origin
Persons who are immunocompromised
Persons with human immunodeficiency virus infection
Persons who have received an organ transplant
Persons who use immunosuppressive medications
Persons who travel on a long-term basis
Information from references 3 and 6.
TABLE 4
Special Travel-Related Risk Factors and
Intervention Risk factor
Consider hepatitis B Travel to area where hepatitis B is endemic
vaccine
May need medical care while abroad
Person living in the United States
but born in another country and who
travels back to country of origin
Consider influenza Travel during influenza season (November
through March in northern hemisphere,
April through September in southern
hemisphere)
Consider Japanese Travel to rural areas of Indian
encephalitis vaccine subcontinent or southeast Asia
Consider polio Travel to country where polio is endemic
vaccine (e.g., India, Nigeria, Pakistan, Egypt,
Afghanistan, Niger, and Somalia)
Age > 65 years
Consider pneumococcal Presence of cardiopulmonary disease,
vaccine asplenia, cirrhosis, diabetes mellitus
Planned prolonged stay in remote area
Planned work near animals or activity
that could attract animals
Consider rabies Unable to report animal bite (e.g.,
vaccine young age, disability, remote location)
The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.
References
(1.) Jong EC. Travel immunizations. Med Clin North Am 1999;83:903-22.
(2.) Jong EC. Immunizations for international travel [Published correction appears in Infect Dis Clin North Am 1999;13:ix]. Infect Dis Clin North Am 1998;12:249-66.
(3.) Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med 2000;342:1716-25.
(4.) Lo Re III V, Gluckman SJ. Prevention of malaria in travelers. Am Fam Physician 2003;68:509-14,515-6.
(5.) Spira AM. Preparing the traveller. Lancet 2003;361: 1368-81.
(6.) Virk A. Medical advice for international travelers. Mayo Clin Proc 2001;76:831-40.
(7.) Gardner P. Immunizations, medications, and common sense for the international traveler. Infect Dis Clin North Am 1990;4:179-97.
(8.) National Center for Infectious Diseases (U.S.), Division of Quarantine. Health information for international travel, 2003-2004. Atlanta, Ga.: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Quarantine, 2003.
(9.) Diptheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991;40(RR-10):1-28.
(10.) Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47(RR-8):1-57.
(11.) Progress toward global eradication of poliomyelitis, 2002. MMWR Morb Mortal Wkly Rep 2003;52:366-9. 12. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-6):1-5.
(13.) Wilson ME. Travel-related vaccines. Infect Dis Clin North Am 2001;15:231-51.
(14.) Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
(15.) Yellow fever vaccine. Recommendations of the Immu-nization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1990;39(RR-6):1-6.
(16.) Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002;34:1369-78.
(17.) Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-51.
(18.) Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994;272:885-9.
(19.) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-12):1-37.
(20.) Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
(21.) Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
(22.) Wolfe MS. Protection of travelers. Clin Infect Dis 1997;25:177-86.
(23.) Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(suppl 1):S44-9.
(24.) Update: recommendations to prevent hepatitis B virus transmission--United States. MMWR Morb Mortal Wkly Rep 1999;48:33-4.
(25.) Advice for travelers. Med Lett Drugs Ther 2002; 44(1128):33-8.
(26.) Steffen R. Immunization against hepatitis A and hepatitis B infections. J Travel Med 2001;8(Suppl 1):S9-16.
(27.) Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993;42(RR-1):1-15.
(28.) Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319:608-14.
(29.) Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002;35:183-8.
(30.) Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1994;43(RR-14):1-7.
(31.) Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-5):1-10.
(32.) Briggs DJ. Rabies vaccination: protecting vulnerable travelers. Infect Med 2002;19:561-5.
(33.) Wilde H, Briggs DJ, Meslin FX, Hemachudha T, Sitprija V. Rabies update for travel medicine advisors. Clin Infect Dis 2003;37:96-100.
(34). Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [Published correction appears in MMWR Morb Mortal Wkly Rep 2000;49:737]. MMWR Recomm Rep 1999;48(RR-1):1-21.
VINCENT LO RE III, M.D., is a postdoctoral research fellow in the Division of Infectious Diseases at the University of Pennsylvania School of Medicine, Philadelphia, where he received his medical degree. He completed a residency in internal medicine and a fellowship in infectious diseases at the Hospital of the University of Pennsylvania, where he was chief resident.
STEPHEN J. GLUCKMAN, M.D., is a professor of medicine and chief of the Infectious Diseases Clinical Services in the Division of Infectious Diseases at the University of Pennsylvania School of Medicine, Philadelphia. He received his medical degree from Columbia University, New York, N.Y., and a certificate of expertise in international and travel medicine from the American Society of Tropical Medicine and Hygiene.
Address correspondence to Vincent Lo Re III, M.D., Division of Infectious Diseases, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, Philadelphia, PA 19104 (e-mail: vincent.lore@uphs.upenn.edu). Reprints are not available from the authors.
COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group